Home › Research › Disparities
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217
Breton Michael Asken, Rosie E. Curiel, Elizabeth Crocco, Melissa J. Armstrong, Shellie-Anne T. Levy, Franchesca Arias, Mónica Rosselli, Idaly Vélez Uribe et al.. The Journal of Prevention of Alzheimer s Disease, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
. Longitudinally, older age (OR=1.14 [1.06-1.22], p<.001), higher levels of p-tau217 (OR=10.37 [3.00-35.02], p<.001) and higher neuropsychiatric symptoms (OR=1.19 [1.02-1.39], p=.023) were associated with higher odds of progression to dementia. MCI is etiologically heterogeneous. The presence of Alzheimer's pathology defined by elevated plasma p-tau217 in individuals with MCI significantly worsens prognosis. Neuropsychiatric symptoms may contribute to cognitive complaints and risk for progressive decline irrespective of AD pathology. Plasma p-tau217 can inform our understanding of base rates of different MCI phenotypes on a larger scale. As with other AD biomarkers, frequency of elevated plasma p-tau217 and odds of progression to dementia requires careful consideration of recruitment source (clinic- vs. community-based), especially across ethno-racially diverse older adults. Ongoing integration of emerging neurodegenerative disease biomarkers with detailed clinical evaluations will continue to improve treatment specificity and prognosis.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 104 participants. In people with mild cognitive impairment, elevated plasma p-tau217 was linked to much higher odds of progressing to dementia, indicating that this blood marker can help define who has Alzheimer's pathology and a worse prognosis. Reported effect size: 52.9%; 49.0%; 68.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Asken, B. M., Curiel, R. E., Crocco, E., Armstrong, M. J., Levy, S.-A. T., Arias, F., et al. (2025). Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2024.100011
Vancouver
Asken BM, Curiel RE, Crocco E, Armstrong MJ, Levy S.-AT, Arias F, et al. Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2024.100011. PMID: 39800468.
BibTeX
@article{asken2025-39800468,
author = {Asken, Breton Michael and Curiel, Rosie E. and Crocco, Elizabeth and Armstrong, Melissa J. and Levy, Shellie-Anne T. and Arias, Franchesca and Rosselli, Mónica and Uribe, Idaly Vélez and others},
title = {{Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217}},
journal = {The Journal of Prevention of Alzheimer s Disease},
year = {2025},
doi = {10.1016/j.tjpad.2024.100011},
pmid = {39800468},
url = {https://doi.org/10.1016/j.tjpad.2024.100011}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Longitudinally, older age (OR=1.14 [1.06-1.22], p<.001), higher levels of p-tau217 (OR=10.37 [3.00-35.02], p<.001) and higher neuropsychiatric symptoms (OR=1.19 [1.02-1.39], p=.023) were associated with higher odds of progression to dementia.
- The presence of Alzheimer's pathology defined by elevated plasma p-tau217 in individuals with MCI significantly worsens prognosis.
- Neuropsychiatric symptoms may contribute to cognitive complaints and risk for progressive decline irrespective of AD pathology.
- Plasma p-tau217 can inform our understanding of base rates of different MCI phenotypes on a larger scale.
- As with other AD biomarkers, frequency of elevated plasma p-tau217 and odds of progression to dementia requires careful consideration of recruitment source (clinic- vs. community-based), especially across ethno-racially diverse older adults.
Why it matters
In people with mild cognitive impairment, elevated plasma p-tau217 was linked to much higher odds of progressing to dementia, indicating that this blood marker can help define who has Alzheimer's pathology and a worse prognosis. The findings are about prognosis and classification, not about a treatment or cure.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Study designcross-sectional
- Participants104
- Effect size52.9%; 49.0%; 68.5%
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 104 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Glenn E. Smith: h-index 104 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Florida: institution h-index 1,303 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39800468) |
| Free to read | 2 / 2 | Free to read |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2024.100011
- PubMed: 39800468
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Disparities from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.